Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Phase 3OCS-01Positive

AI Analysis

Summary

Oculis announced completion of the final patient visit in its Phase 3 DIAMOND trial of OCS-01 eye drops for diabetic macular edema, with topline results expected in June 2026.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Completion of final patient visit in Phase 3 DIAMOND program

Importance:6/10

Sentiment:

0.60

Phase 3 completionOphthalmologyDiabetic Macular EdemaTopline results expected

Related Companies

$OCS

Read the original article

Published by GlobeNewswire Clinical Studies on April 20, 2026 8:00 AM

Read Original